| Inhibition . | Drug . | Approved in PsO . | Approved in PsA . |
|---|---|---|---|
| TNF | Infliximab | Yes | Yes |
| Adalimumab | Yes | Yes | |
| Golimumab | No | Yes | |
| Certolizumab | Yes | Yes | |
| Etanercept | Yes | Yes | |
| IL-17A | Secukinumab | Yes | Yes |
| Ixekizumab | Yes | Yes | |
| Brodalumab | Yes | No | |
| IL-17A/F | Bimekizumab | Yes | Yes |
| CTLA-4 | Abatacept | No | Yes |
| IL-12/23 | Ustekinumab | Yes | Yes |
| IL-23 | Guselkumab | Yes | Yes |
| Risankizumab | Yes | Yes | |
| Tildrakizumab | Yes | No | |
| PDE4 | Apremilast | Yes | Yes |
| JAK | Tofacitinib | No | Yes |
| Upadacitinib | No | Yes |
| Inhibition . | Drug . | Approved in PsO . | Approved in PsA . |
|---|---|---|---|
| TNF | Infliximab | Yes | Yes |
| Adalimumab | Yes | Yes | |
| Golimumab | No | Yes | |
| Certolizumab | Yes | Yes | |
| Etanercept | Yes | Yes | |
| IL-17A | Secukinumab | Yes | Yes |
| Ixekizumab | Yes | Yes | |
| Brodalumab | Yes | No | |
| IL-17A/F | Bimekizumab | Yes | Yes |
| CTLA-4 | Abatacept | No | Yes |
| IL-12/23 | Ustekinumab | Yes | Yes |
| IL-23 | Guselkumab | Yes | Yes |
| Risankizumab | Yes | Yes | |
| Tildrakizumab | Yes | No | |
| PDE4 | Apremilast | Yes | Yes |
| JAK | Tofacitinib | No | Yes |
| Upadacitinib | No | Yes |
No: drug not currently approved/licensed; Yes: drug currently approved/licensed. JAK: Janus kinases; PDE4: phosphodiesterase 4; PsA: psoriatic arthritis; PsO: psoriasis.
| Inhibition . | Drug . | Approved in PsO . | Approved in PsA . |
|---|---|---|---|
| TNF | Infliximab | Yes | Yes |
| Adalimumab | Yes | Yes | |
| Golimumab | No | Yes | |
| Certolizumab | Yes | Yes | |
| Etanercept | Yes | Yes | |
| IL-17A | Secukinumab | Yes | Yes |
| Ixekizumab | Yes | Yes | |
| Brodalumab | Yes | No | |
| IL-17A/F | Bimekizumab | Yes | Yes |
| CTLA-4 | Abatacept | No | Yes |
| IL-12/23 | Ustekinumab | Yes | Yes |
| IL-23 | Guselkumab | Yes | Yes |
| Risankizumab | Yes | Yes | |
| Tildrakizumab | Yes | No | |
| PDE4 | Apremilast | Yes | Yes |
| JAK | Tofacitinib | No | Yes |
| Upadacitinib | No | Yes |
| Inhibition . | Drug . | Approved in PsO . | Approved in PsA . |
|---|---|---|---|
| TNF | Infliximab | Yes | Yes |
| Adalimumab | Yes | Yes | |
| Golimumab | No | Yes | |
| Certolizumab | Yes | Yes | |
| Etanercept | Yes | Yes | |
| IL-17A | Secukinumab | Yes | Yes |
| Ixekizumab | Yes | Yes | |
| Brodalumab | Yes | No | |
| IL-17A/F | Bimekizumab | Yes | Yes |
| CTLA-4 | Abatacept | No | Yes |
| IL-12/23 | Ustekinumab | Yes | Yes |
| IL-23 | Guselkumab | Yes | Yes |
| Risankizumab | Yes | Yes | |
| Tildrakizumab | Yes | No | |
| PDE4 | Apremilast | Yes | Yes |
| JAK | Tofacitinib | No | Yes |
| Upadacitinib | No | Yes |
No: drug not currently approved/licensed; Yes: drug currently approved/licensed. JAK: Janus kinases; PDE4: phosphodiesterase 4; PsA: psoriatic arthritis; PsO: psoriasis.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
